Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

被引：0
|
作者：
G Hofstetter
A Berger
E Schuster
A Wolf
G Hager
I Vergote
I Cadron
J Sehouli
E I Braicu
S Mahner
P Speiser
C Marth
A G Zeimet
H Ulmer
R Zeillinger
N Concin
机构：
[1] Innsbruck Medical University,Department of Gynecology and Obstetrics
[2] Molecular Oncology Group,Department of Obstetrics and Gynecology
[3] Medical University of Vienna,Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology
[4] Universitaire Ziekenhuzen Leuven,Department of Gynecology
[5] Katholieke Universiteit Leuven,Department of Gynecology and Gynecologic Oncology
[6] European Competence Center for Ovarian Cancer,Department of Medical Statistics
[7] Campus Virchow Klinikum,undefined
[8] Charité – Universitätsmedizin Berlin,undefined
[9] University Medical Center Hamburg-Eppendorf,undefined
[10] Informatics,undefined
[11] and Health Economics,undefined
[12] Innsbruck Medical University,undefined
来源：
British Journal of Cancer | 2011年 / 105卷
关键词：
ovarian cancer; delta133p53; p53 isoforms; p53; p73;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1593 / 1599
页数：6
相关论文
共 50 条
  • [41] Some aspects of mutant p53 in ovarian cancer biology
    Heublein, Sabine
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S546 - S547
  • [42] Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α
    Roselle, Christopher
    Horikawa, Izumi
    Chen, Linhui
    Kelly, Andre R.
    Gonzales, Donna
    Da, Tong
    Wellhausen, Nils
    Rommel, Philipp C.
    Baker, Daniel
    Suhoski, Megan
    Scholler, John
    O'Connor, Roddy S.
    Young, Regina M.
    Harris, Curtis C.
    June, Carl H.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (10)
  • [43] Prognostic significance of mutant p53 in breast cancer patients
    Castiglione, F
    Sarotto, I
    Destefanis, M
    Ricco, MT
    Porcile, G
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S24 - S24
  • [44] p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer
    Eltabbakh, GH
    Belinson, JL
    Kennedy, AW
    Biscotti, CV
    Casey, G
    Tubbs, RR
    Blumenson, LE
    CANCER, 1997, 80 (05) : 892 - 898
  • [45] p53 expression as a prognostic marker in inflammatory breast cancer
    Gonzalez-Angulo, AM
    Sneige, N
    Buzdar, AU
    Valero, V
    Kau, SW
    Broglio, K
    Yamamura, Y
    Hortobagyi, GN
    Cristofanilli, M
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6215 - 6221
  • [46] Mutant p53 in colon cancer
    Nakayama, Mizuho
    Oshima, Masanobu
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (04) : 267 - 276
  • [47] P53 a prognostic marker in Wilms' Tumor
    Hermanns, M
    Rohrmann, D
    Richter, AP
    Büttner, R
    Malone, M
    Jakse, G
    JOURNAL OF UROLOGY, 2004, 171 (04): : 148 - 149
  • [48] p53 is an independent prognostic factor for survival in thyroid cancer
    Bachmann, Kai
    Pawliska, Denise
    Kaifi, Jussuf
    Schurr, Paulus
    Zoerb, Jennifer
    Mann, Oliver
    Kahl, Hans J.
    Izbicki, Jakob R.
    Strate, Tim
    ANTICANCER RESEARCH, 2007, 27 (6B) : 3993 - 3997
  • [49] EXPRESSION OF MUTANT P53 PROTEIN IN METASTASIZING MEDULLOBLASTOMA AND PNET - A PROGNOSTIC MARKER
    SCHEURLEN, W
    PETRASCH, K
    HUPPERTZ, HI
    KUHL, J
    AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1993, 15 (01): : 137 - 138
  • [50] P53 NUCLEAR OVEREXPRESSION MAY NOT BE AN INDEPENDENT PROGNOSTIC MARKER IN EARLY COLORECTAL-CANCER
    GREWAL, H
    GUILLEM, JG
    KLIMSTRA, DS
    COHEN, AM
    DISEASES OF THE COLON & RECTUM, 1995, 38 (11) : 1176 - 1181
12345